Who makes Kali bichromicum 10-60 (C30)?

Kali bichromicum 10-60 (C30) is developed by Shaare Zedek Medical Center.

What development phase is Kali bichromicum 10-60 (C30) in?

Kali bichromicum 10-60 (C30) is in Phase 3.

Last reviewed 2026-05-15 · How we verify

Kali bichromicum 10-60 (C30)

Shaare Zedek Medical Center · Phase 3 active Small molecule

Kali bichromicum is a homeopathic potentized preparation of potassium dichromate used in homeopathic medicine, with no established conventional pharmacological mechanism.

At a glance

Generic name	Kali bichromicum 10-60 (C30)
Sponsor	Shaare Zedek Medical Center
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Kali bichromicum (potassium dichromate) at homeopathic potencies (C30 represents 10^-60 dilution) operates under homeopathic principles rather than conventional pharmacology. At such extreme dilutions, no molecular target or active ingredient is expected to remain. Homeopathic remedies are based on the principle of 'like cures like' and are not supported by conventional pharmacological evidence.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of Homeopathic Remedy Kalium Bichromicum on Viscosity and Amount of Sputum Mechanically Ventilated ICU Patients. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Kali bichromicum 10-60 (C30) CI brief — competitive landscape report
Kali bichromicum 10-60 (C30) updates RSS · CI watch RSS
Shaare Zedek Medical Center portfolio CI